<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69065">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206711</url>
  </required_header>
  <id_info>
    <org_study_id>AI468-036</org_study_id>
    <nct_id>NCT02206711</nct_id>
  </id_info>
  <brief_title>Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.</brief_title>
  <official_title>Pharmacokinetics and Metabolism of [14C] BMS-955176 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics (PK), metabolism, routes and
      extent of elimination, safety and tolerability of a single oral dose of [14C] BMS-955176 in
      healthy male subjects. There is no formal research hypothesis to be statistically tested for
      this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To asses the PK (AUC, Cmax) of a single oral dose</measure>
    <time_frame>Day 1 through Day 13 (predose to 288 hours)</time_frame>
    <description>Serial blood samples for PK parameters determined from plasma concentration versus time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate extent of elimination of a single oral dose (% TRA recovery)</measure>
    <time_frame>Day 1 through Day 13 (predose to 288 hours)</time_frame>
    <description>Sample of urinary/fecal/bile will be collected for determining total recovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>Day 1 through Day 13</time_frame>
    <description>Safety assessments based on review of adverse events, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Single oral dose of [14C] BMS 955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 180 mg oral dose of [14C] BMS-955176 containing approximately 80 microcurie of total radioactivity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasoduodenal (ND) Tube Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of [14C] BMS 955176 on Day 1 with ND placement 1 hour post dose to facilitate continuous bile collection though 8 hours post dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-955176</intervention_name>
    <description>Single dose of drug on Day 1</description>
    <arm_group_label>Single oral dose of [14C] BMS 955176</arm_group_label>
    <arm_group_label>Nasoduodenal (ND) Tube Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male subjects

          -  Ages 18-50 years

          -  Body weight of at least 110 lbs (50kg)

          -  BMI of 18 to 32 kg/m^2

          -  non-smoking

        Exclusion Criteria:

          -  Clinically significant diagnostic or therapeutic radiation exposure within the
             previous 12 months (eg serial X-ray or CAT scans, barium meals).

          -  gastrointestinal disease including gastrointestinal surgery

          -  constipation or irregular bowel movements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 11, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
